Bexobrutideg (NX-5948) is a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader that Breaks Established Design Rules for CNS Drugs By webmaster / April 25, 2025
NX-5948 and NX-2127 Potently Degrade a Broad Array of Clinically-Relevant BTK Mutants That Display Resistance to Inhibitors and Other BTK Degraders By webmaster / March 25, 2025
IRAK4 Degrader GS-6791 Inhibits TLR And IL-1R-Driven Inflammatory Signaling, And Ameliorates Disease In A Preclinical Arthritis Model By aterrado@waterhousebrands.com / January 7, 2025
An Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader For The Treatment Of Primary And Inhibitor-Resistant Solid Tumors By aterrado@waterhousebrands.com / January 7, 2025
NX-5948 Promotes Selective, Sub-Nanomolar Degradation Of Inhibitor-Resistant BTK Mutants By aterrado@waterhousebrands.com / January 7, 2025
First Disclosure Of NX-5948, An Oral Targeted Degrader Of Bruton’s Tyrosine Kinase (BTK) For The Treatment Of B-Cell Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-5948: BTK Degrader with Activity in Lymphoid Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-5948, A Clinical-Stage BTK Degrader, Achieves Deep Suppression Of BCR, TLR, And Fcr Signaling In Immune Cells And Demonstrates Efficacy In Preclinical Models Of Arthritis And Other Inflammatory Diseases By aterrado@waterhousebrands.com / January 7, 2025
Efficacy And Safety Of The Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From An Ongoing Phase 1A/B Study By aterrado@waterhousebrands.com / January 7, 2025
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies By dev@sirosolutions.com / December 17, 2024
